Thomas L. Chenevert1, Craig J. Galban1, Daniel A. Hamstra2, Christina I. Tsien2, Larry R. Junck3, Pia C. Sundgren1, Charles R. Meyer1, Marko K. Ivancevic1,4, Thomas C. Kwee1, Suzan E. Rohrer1, Brian D. Ross1
1Radiology - MRI, University of Michigan, Ann Arbor, MI, USA; 2Radiation Oncology, University of Michigan, Ann Arbor, MI, USA; 3Neurology, University of Michigan, Ann Arbor, MI, USA; 4MRI, Philips Medical Systems, Cleveland, OH, USA
Therapy-induced alteration of tumor cellularity and perfusion suggests diffusion and perfusion may serve as treatment-response biomarkers. Voxel-by-voxel differences of spatially-registered ADC and/or perfusion maps have shown promise. Prior approaches have utilized ADC and perfusion as stand-alone biomarkers. In this study, we explore use of co-alignment of ADC with perfusion maps, as well as over the pre-Tx to early-Tx interval such that patterns of simultaneous change in ADC and perfusion within each voxel are determined. The fractional volume of tumor voxels exhibiting significant change with therapy in this dual-parameter space is tested as a biomarker of patient overall survival.